Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Amit Singh, senior director of capital markets; Neal Masia, assistant treasurer and VP; John Croke, senior manager of pensions; Renje Kuo, manager of capital markets; and Colum Lane, director of pension investments
The defined-benefit (DB) pension plan is beginning to play a bigger role in liquidity forecasting and planning at $67 billion Pfizer. The financial crisis and slide in interest rates created volatility in the funded status of many DB plans. Pfizer’s plan was fully funded in 2006, but fell to 81% funded by 2011. While the company has made cash contributions to the plan to shore up the assets and while asset valuations have rebounded, these pluses have largely been offset by a sharp rise in pension liabilities resulting from lower discount rates.

Pfizer recently decided to move from a DB plan to an enhanced savings plan, which will be completed by 2018. Until then, it needed a sophisticated, reliable model to support planning for pension liquidity and its earnings-per-share impact. The pension world is full of predictive models, but Pfizer wanted something more integrated and customized, so it built its own better mousetrap at a cost of over 500 man-hours.

Treasury and Risk

Treasury and Risk Staff Writers

More from this author

Treasury & Risk

Join Treasury & Risk

Don’t miss crucial treasury and finance news along with in-depth analysis and insights you need to make informed treasury decisions. Join Treasury & Risk now!

  • Free unlimited access to Treasury & Risk including case studies with corporate innovators, informative newsletters, educational webcasts, and resources from industry leaders.
  • Exclusive discounts on ALM and Treasury & Risk events.
  • Access to other award-winning ALM publications including PropertyCasualty360.com and Law.com.

Already have an account? Sign In Now
Join Treasury & Risk

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.